SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.3

Change

+0.01 (+3.48)%

Market Cap

N/A

Volume

532.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

N/A

USD 246.77B
AMGN Amgen Inc

N/A

USD 160.19B
SNY Sanofi ADR

N/A

USD 118.11B
GILD Gilead Sciences Inc

N/A

USD 80.61B
BIIB Biogen Inc

N/A

USD 32.82B
GRFS Grifols SA ADR

N/A

USD 6.19B
AMRN Amarin Corporation PLC

N/A

USD 0.32B
SCLX Scilex Holding Company

N/A

USD 0.20B
MIRA MIRA Pharmaceuticals Inc. Comm..

N/A

USD 0.01B

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.67% 40% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.67% 40% F 29% F
Trailing 12 Months  
Capital Gain -81.60% 22% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.60% 22% F 7% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.73% 44% F 26% F
Dividend Return -10.73% 44% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.62% 22% F 38% F
Risk Adjusted Return -23.52% 44% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector